A Drug-Safety Group Asked the FDA to Block Compounding of Seven Peptides. Here Is What the Petition Says
The short version
- The Partnership for Safe Medicines (PSM), a drug-safety advocacy group, announced on 21 October that it had filed a citizen petition asking the FDA not to allow compounding of seven peptides: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon.
- The petition asks the FDA to refrain from every route: a rule, a place in "Category 1" of its interim compounding policy, or enforcement discretion. It also asks the FDA not to rely on the July advisory committee vote.
- Its main grounds are the FDA's own staff reviews, which proposed against all seven, and alleged conflicts of interest among committee members. These are PSM's claims, not findings by the FDA.
- The petition is a request, not a ruling. We found no FDA response and no docket number on 27 October, and the White House review of the FDA's separate "Interim Access Policy" was still pending.
- Nothing changes today for anyone buying or selling research peptides. If the FDA grants the request, the pharmacy route that policy is reported to open would stay closed.
On 21 October the Partnership for Safe Medicines (PSM) said it had filed a citizen petition asking the FDA to block compounding of seven peptides and to set aside the advisory committee vote that recommended six of them. It lands while the White House reviews the FDA policy that could open the pharmacy route. Here is what the petition asks, what it argues, and what is still only an argument, as of 27 October 2026.
What the petition asks
PSM filed under 21 C.F.R. 10.30, the FDA rule that lets any person ask the agency to take or refrain from an action. The copy on PSM's site is headed "Submitted via Regulations.gov October 23, 2026"; PSM's press release announcing the filing is dated 21 October. We report both dates because they differ, and we have not been able to find the petition's docket number.
| Question | Answer, from the petition |
|---|---|
| Which peptides? | BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon, the seven considered at the FDA's Pharmacy Compounding Advisory Committee (PCAC) on 23 and 24 July |
| What action does it want the FDA to avoid? | Allowing compounding with any of the seven "whether through regulation, addition to 'Category 1' under FDA's guidance on 'Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A' ... or otherwise through exercise of enforcement discretion or any other action" |
| What else? | That the FDA "refrain from relying on" the July committee to meet its legal duty to consult an advisory committee before writing rules for the 503A bulks list |
| Who filed it? | PSM, which describes itself as "a public health group of non-profit organizations" |
Source: PSM citizen petition (PDF, 8 pages) and PSM press release of 21 October 2026, both read on 27 October 2026.
The petition's grounds
1. The FDA's own staff said no
The petition quotes the FDA's briefing documents for the July meeting and says agency staff proposed not adding any of the seven to the 503A bulks list. We checked the BPC-157, KPV and TB-500 passages against the FDA documents. For BPC-157: "On balance, the physicochemical characterization, information on historical use, lack of evidence of effectiveness, and safety information identified for both BPC-157 (free base) and BPC-157 acetate weigh against them being added to the 503A Bulks List." The FDA's briefing documents also say it "did not find any information on the use of KPV" in humans and found no medical literature in which TB-500 "was administered to patients to treat any disease or condition".
2. The committee vote, as PSM argues it
The PCAC voted in July to recommend six of the seven. Our page on the vote has every tally. PSM argues the committee was not properly constituted under the Federal Advisory Committee Act and the Ethics in Government Act, because newly added members include people whose clinics or businesses offer peptides. It cites STAT reporting of 29 June 2026 and a Washington Post report of 17 July on staff concerns about the appointments, and says it is "not aware of any waivers" for these members. It also says the committee's United States Pharmacopeia (USP) representative voted against all seven. These are PSM's allegations. The FDA has not responded to them in anything we could find.
3. "Regulate it" is not a listed criterion
The petition answers the arguments made for adding the peptides. On the claim that people are buying them illegally anyway and a regulated route is safer, PSM says that is not one of the criteria in the FDA's rule, and that the answer to illegal distribution is "enforcement", not "legalization". It makes the same legal-criteria point about calls for guardrails, for real-world data and for more adverse event reports. The other side is on the record too: the Alliance for Pharmacy Compounding has asked the FDA for interim enforcement discretion with conditions "including enhanced disclosures to patients, serious adverse event reporting and data collection on peptide use", as the Washington Post reported on 7 October.
What PSM says it bought
PSM's press release says its researchers ordered peptides from four state-licensed 503A compounding pharmacies in Texas and Pennsylvania, shipped to California. It says three of the four have no known California licences, the fourth lacks a non-resident sterile compounding licence, none of the products was labelled "research use only", and all arrived with syringes and injection instructions. These are PSM's own purchases and its own account. The release does not name the pharmacies or say which peptides were bought, and we have not verified them.
Where it sits next to the White House review
| Item | Status on 27 October 2026 |
|---|---|
| PSM citizen petition | Announced 21 October. PSM says the FDA "is required to respond within 180 days". We found no FDA response and no docket number. |
| FDA "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94) | Still "Pending Review" at the White House, received 14 October. Text and peptides not public. |
| Outside meetings on that policy | Six logged. The 27 and 28 October meetings were still listed as "Scheduled" when we read the log. |
| Federal Register | No FDA document mentioning "peptide" since 20 October. |
Source: reginfo.gov listing and meeting log for RIN 0910-ZD94, and the Federal Register API, all read on 27 October 2026. The White House filing does not say which legal mechanism the policy uses, so we cannot say whether the petition's closing of the enforcement-discretion route would reach it. The filing is covered in our report on the policy at the White House.
What would not change
- Nothing today. A citizen petition does not bind the FDA, which can grant it, deny it or reply that it has not yet decided.
- The legal status of research peptides. The petition concerns compounding by pharmacies. It does not change the rules for products labelled for research use only, covered in are peptides legal in the US.
- The advisory committee vote, which was non-binding from the start.
What to watch
- A docket number and the FDA's reply, which would appear on regulations.gov.
- The reginfo.gov status of RIN 0910-ZD94, and a Federal Register notice or FDA page with the policy text.
- Whether and when the FDA posts the petition to a public docket.
We will update this piece the day a document is published. Every regulator action on peptides we have verified is in the enforcement tracker.
Questions readers ask
What is the Partnership for Safe Medicines petition?
A citizen petition under 21 C.F.R. 10.30, announced by PSM on 21 October 2026, asking the FDA not to allow compounding with BPC-157, KPV, TB-500, MOTS-c, emideltide, semax or epitalon, whether by rule, by placing them in Category 1 of its interim policy, or by enforcement discretion.
Does the petition stop the FDA's peptide policy?
No. A citizen petition is a request. It does not bind the FDA. On 27 October 2026 the FDA's separate Interim Access Policy for Compounding Using Certain Peptides was still pending White House review and its text was not public.
Why does PSM say the advisory committee vote should be set aside?
PSM argues the committee was not properly constituted under the Federal Advisory Committee Act and the Ethics in Government Act because new members include people whose businesses offer peptides, and says it knows of no conflict waivers. These are PSM's allegations; the FDA has not responded to them in anything we found.
Has the FDA responded to the petition?
Not that we could find on 27 October 2026. PSM says the FDA is required to respond within 180 days. We also could not find a docket number for it.
What does this mean for people who buy research peptides?
Nothing changes today. The petition concerns pharmacy compounding, not products sold for research use only. If the FDA grants it, the pharmacy route reported in connection with the White House policy would stay closed for these seven peptides.
Sources
- Partnership for Safe Medicines: Citizen Petition to the FDA (PDF), headed 23 October 2026; read 27 October 2026
- Partnership for Safe Medicines: press release, PSM Files Citizen Petition Urging FDA to Block Compounding of Unapproved and Uncharacterized Peptides, 21 October 2026
- FDA: Briefing document for the 23 July 2026 PCAC meeting, BPC-157 related bulk drug substances, read 27 October 2026
- FDA: Briefing document for the 23 July 2026 PCAC meeting, KPV related bulk drug substances, read 27 October 2026
- FDA: Briefing document for the 23 July 2026 PCAC meeting, TB-500 related bulk drug substances, read 27 October 2026
- reginfo.gov: Pending EO 12866 Regulatory Review, RIN 0910-ZD94, read 27 October 2026
- reginfo.gov: EO 12866 meetings for RIN 0910-ZD94, read 27 October 2026
- RAPS Regulatory Focus: This Week at FDA: Peptide dispute, clinical trial legislation, and more (Joanne S. Eglovitch), 23 October 2026
- Washington Post: Trump administration paving way for temporary sale of some unapproved peptides, 7 October 2026
- Federal Register API: FDA documents mentioning "peptide" published since 20 October 2026, queried 27 October 2026